Is tirzepatide still on the FDA drug shortage list?

Is tirzepatide still on the FDA shortage list?

No. As of Nov 15, 2026, FDA’s drug shortage data, read through openFDA, lists no tirzepatide product with status “Current.” FDA’s Drug Shortages Database page for Tirzepatide Injection shows the status “Resolved.” FDA determined the tirzepatide injection shortage resolved on Dec 19, 2024, after first listing it on Dec 15, 2022.

Checked Nov 15, 2026 against FDA’s drug shortage data through openFDA, and Nov 15, 2026 against FDA’s Drug Shortages Database page for Tirzepatide Injection. Shortage status can change; FDA’s database is the current word.

Tirzepatide on FDA’s shortage list, by date

FDA’s words or recordSource
Dec 15, 2022Listed“Tirzepatide injection products were first added to FDA’s drug shortage list on December 15, 2022.”FDA Declaratory Order, December 19, 2024: Resolution of Shortages of Tirzepatide Injection Products (Mounjaro and Zepbound)
April 2024Listed“The Zepbound pen products were approved by FDA in November 2023 (NDA 217806) and added to FDA’s drug shortage list in April 2024 due to high demand.”FDA Declaratory Order, December 19, 2024: Resolution of Shortages of Tirzepatide Injection Products (Mounjaro and Zepbound)
Oct 2, 2024Resolved“The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. Tirzepatide injection has been in shortage since 2022 due to increased demand.”FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
Oct 22, 2024Litigation“As part of litigation, the decision to remove tirzepatide from the FDA drug shortage list has been remanded to the agency for reevaluation.”FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
Dec 19, 2024Resolved“This order revokes and replaces FDA’s October 2, 2024 decision on the same subject. I. Determination FDA determines that the tirzepatide injection product shortage is resolved.”FDA Declaratory Order, December 19, 2024: Resolution of Shortages of Tirzepatide Injection Products (Mounjaro and Zepbound)
Feb 18, 2025503A grace period end“For state-licensed pharmacists or physicians compounding under section 503A of the FD&C Act, 60 calendar days from the date of this order, until February 18, 2025”FDA Declaratory Order, December 19, 2024: Resolution of Shortages of Tirzepatide Injection Products (Mounjaro and Zepbound)
Mar 5, 2025Litigation“On March 5, 2025, the district court denied the plaintiffs’ preliminary injunction motion in Outsourcing Facilities Association v. FDA, 4:24-cv-00953 (N.D. Tex.).”FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
Mar 19, 2025503B grace period end“For outsourcing facilities under section 503B of the FD&C Act, 90 calendar days from the date of this order, until March 19, 2025.”FDA Declaratory Order, December 19, 2024: Resolution of Shortages of Tirzepatide Injection Products (Mounjaro and Zepbound)
Apr 1, 2026Status statement“Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list.”FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize

FDA’s most recent statement

What the end of the shortage meant for compounding

FDA set dates after which it would act on compounding that depended on tirzepatide being in shortage: February 18, 2025 for state-licensed pharmacies and physicians (section 503A) and March 19, 2025 for outsourcing facilities (section 503B). The rules FDA states now are on Is compounded tirzepatide still legal?. All GLP-1 drugs: shortage history.

Common questions

When was tirzepatide added to the shortage list?

FDA’s December 19, 2024 order says tirzepatide injection products were first added on December 15, 2022, with the Zepbound pens added in April 2024.

When did FDA say the tirzepatide shortage was resolved?

October 2, 2024, and again on December 19, 2024 after a court sent the first decision back to FDA for reevaluation.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.